LNTH (Lantheus Holdings) Financial Strength: 7 (As of Jun. 2026) — 17% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LNTH Lantheus Holdings Inc LNTH
80 GF Score
Price $100.96
GF Value $91.09
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Lantheus Holdings Financial Strength?

Lantheus Holdings LNTH 80 Financial Strength is 7 as of Jun. 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates LNTH with a GF Score™ of 80/100 and a GF Value™ of $91.09 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Lantheus Holdings has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Lantheus Holdings's Interest Coverage for the quarter that ended in Jun. 2026 was 20.39. Lantheus Holdings's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.40. As of today, Lantheus Holdings's Altman Z-Score is 5.60.


Lantheus Holdings  (NAS:LNTH) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Lantheus Holdings has the Financial Strength Rank of 7.


Lantheus Holdings Financial Strength Related Terms


LNTH vs HIMS, AMRX, KNSA: Financial Strength Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings Financial Strength vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Financial Strength distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Financial Strength falls into.


LNTH
80GF Score
Lantheus Holdings Inc LNTH
Financial Strength is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lantheus Holdings Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Lantheus Holdings's Interest Expense for the months ended in Jun. 2026 was $-5 Mil. Its Operating Income for the months ended in Jun. 2026 was $100 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $624 Mil.

Lantheus Holdings's Interest Coverage for the quarter that ended in Jun. 2026 is

Interest Coverage=-1*Operating Income (Q: Jun. 2026 )/Interest Expense (Q: Jun. 2026 )
=-1*100.215/-4.915
=20.39

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Lantheus Holdings's Debt to Revenue Ratio for the quarter that ended in Jun. 2026 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2026 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.697 + 624.261) / 1552.72
=0.40

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Lantheus Holdings has a Z-score of 5.60, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 5.6 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Financial Strength →
What does a Financial Strength of 7 mean?
Lantheus Holdings (LNTH) has a Financial Strength of 7 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Lantheus Holdings and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Lantheus Holdings' Financial Strength has ranged from 3.00 to 8.00.
Is Lantheus Holdings' Financial Strength too high?
Lantheus Holdings' current Financial Strength of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. Overall, Lantheus Holdings has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Financial Strength compare to HIMS and AMRX?
Lantheus Holdings' Financial Strength of 7 can be compared against companies in the Drug Manufacturers industry. Historically, Lantheus Holdings' own Financial Strength has ranged from 3.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Drug Manufacturers company?
A good Financial Strength depends on the Drug Manufacturers industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Lantheus Holdings and its competitors. Lantheus Holdings's current Financial Strength is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $91.09, compared to a current price of $100.96 — trading 10.8% above its estimated fair value. The current Financial Strength is 7, which is 17% above median its 10-year median of 6.00. Lantheus Holdings' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Financial Strength is 7 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lantheus Holdings (LNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued. The current stock price of $100.96 is trading 10.8% above its estimated GF Value™ of $91.09. GuruFocus considers Lantheus Holdings to be Modestly Overvalued.

Key valuation signals for LNTH:

  • Financial Strength: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: $91.09 vs. price of $100.96 (10.8% above fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lantheus Holdings Business Description

Other Exchanges 1LNTH:Italy0L8:Germany
Address 201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
80GF Score

Get the complete analysis for LNTH

Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$100.96
Price
$91.09
GF Value